News & Updates

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

05 May 2022

New drug applications approved by US FDA as of 16-30 April 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

05 May 2022

Guselkumab promising for Crohn’s disease

28 Apr 2022

In Crohn’s disease patients with inadequate response or intolerance to conventional or biologic therapy, guselkumab, a selective p19 interleukin (IL)-23 antagonist, appears effective by yielding better clinical and endoscopic improvements than placebo, a recent study has found.

Guselkumab promising for Crohn’s disease

28 Apr 2022

Hypertriglyceridemia tied with severe acute pancreatitis

27 Apr 2022

The risk of severe acute pancreatitis appears to be significantly and independently associated with hypertriglyceridemia, reports a recent study.

Hypertriglyceridemia tied with severe acute pancreatitis

27 Apr 2022

Whole grain vs refined wheat foods do not differ in glycaemic response, gastric emptying

21 Apr 2022

Whole grain wheat foods boast of several health benefits but, in their natural composition, do not provide lower postprandial glycaemia or gastric emptying relative to their refined wheat counterparts, reveals a recent study.

Whole grain vs refined wheat foods do not differ in glycaemic response, gastric emptying

21 Apr 2022

Faecal microbiota transplant safe, effective for recurrent CDI

21 Apr 2022

Faecal microbiota transplantation (FMT) may be an effective intervention for recurrent Clostridioides difficile infection (CDI), leading to high clinical cure and low complication rates, reports a new real-world study.

Faecal microbiota transplant safe, effective for recurrent CDI

21 Apr 2022

Treatment strategies, clinical variables predict relapse in paediatric CD

19 Apr 2022

The past decade has seen a decline in clinical relapses of paediatric luminal Crohn’s disease (CD), according to a study. Relapse risk is associated with clinical, endoscopic, histological, and laboratory variables and treatment strategies.

Treatment strategies, clinical variables predict relapse in paediatric CD

19 Apr 2022

$Group CBT with interoceptive exposure safe, effective for drug-refractory IBS$

Group CBT with interoceptive exposure safe, effective for drug-refractory IBS

18 Apr 2022

Group cognitive behavioural therapy (GCBT) with interoceptive exposure (IE) is not only safe and effective but also an efficient treatment option for individuals with drug-refractory irritable bowel syndrome (IBS), according to a Japan study.

Group CBT with interoceptive exposure safe, effective for drug-refractory IBS

18 Apr 2022

Original New Drug Application Approvals by US FDA (01 - 15 April 2022)

18 Apr 2022

New drug applications approved by US FDA as of 01-15 April 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 April 2022)

18 Apr 2022

Gluten exerts null effect on youth with gastrointestinal symptoms

18 Apr 2022

The addition of gluten to the diet is detrimental to neither the gastrointestinal (GI) symptoms in young people nor their mental health, according to a study.

Gluten exerts null effect on youth with gastrointestinal symptoms

18 Apr 2022

Wild-type GIST: Who does it affect and where does it typically originate?

15 Apr 2022

Wild-type gastrointestinal stromal tumours (GIST), though rare, tend to develop more frequently in older adults and commonly originate in the stomach or small intestine, a recent study has found. Though treatment options are limited, surgical resection and systemic therapy remain the principal modalities.

Wild-type GIST: Who does it affect and where does it typically originate?

15 Apr 2022

News & Updates

Filter by Specialty:

Specialty:

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

Original New Drug Application Approvals by US FDA (16 - 30 April 2022)

Guselkumab promising for Crohn’s disease

Guselkumab promising for Crohn’s disease

Hypertriglyceridemia tied with severe acute pancreatitis

Hypertriglyceridemia tied with severe acute pancreatitis

Whole grain vs refined wheat foods do not differ in glycaemic response, gastric emptying

Whole grain vs refined wheat foods do not differ in glycaemic response, gastric emptying

Faecal microbiota transplant safe, effective for recurrent CDI

Faecal microbiota transplant safe, effective for recurrent CDI

Treatment strategies, clinical variables predict relapse in paediatric CD

Treatment strategies, clinical variables predict relapse in paediatric CD

Group CBT with interoceptive exposure safe, effective for drug-refractory IBS

Group CBT with interoceptive exposure safe, effective for drug-refractory IBS

Original New Drug Application Approvals by US FDA (01 - 15 April 2022)

Original New Drug Application Approvals by US FDA (01 - 15 April 2022)

Gluten exerts null effect on youth with gastrointestinal symptoms

Gluten exerts null effect on youth with gastrointestinal symptoms

Wild-type GIST: Who does it affect and where does it typically originate?

Wild-type GIST: Who does it affect and where does it typically originate?